An Engineered Influenza a Virus Expressing the Co-Stimulator OX40L as an Oncolytic Agent Against Hepatocellular Carcinoma
Hao Yang,Guanglin Lei,Zhuoya Deng,Fang Sun,Yuying Tian,Jinxia Cheng,Hongyu Yu,Cong Li,Changqing Bai,Shaogeng Zhang,Guangwen An,Penghui Yang
DOI: https://doi.org/10.2147/jhc.s410703
2024-01-10
Journal of Hepatocellular Carcinoma
Abstract:Hao Yang, 1– 3, &ast Guanglin Lei, 2, &ast Zhuoya Deng, 1 Fang Sun, 1 Yuying Tian, 1 Jinxia Cheng, 1 Hongyu Yu, 1 Cong Li, 1 Changqing Bai, 4 Shaogeng Zhang, 2 Guangwen An, 5 Penghui Yang 1 1 Faculty of Hepato-Pancreato-Biliary Surgery, Institute of Hepatobiliary Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing, People's Republic of China; 2 Department of Hepatological Surgery, the Fifth Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China; 3 Department of Surgery, Taian City Central Hospital, Taian, People's Republic of China; 4 Department of Respiratory, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Guangdong, People's Republic of China; 5 Department of Pharmacy, No. 984 Hospital of the PLA, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Penghui Yang; Guangwen An, Email ; Background: Oncolytic virus (OV) therapy has emerged as a promising novel form of immunotherapy. Moreover, an increasing number of studies have shown that the therapeutic efficacy of OV can be further improved by arming OVs with immune-stimulating molecules. Methods: In this study, we used reverse genetics to produce a novel influenza A virus, termed IAV-OX40L, which contained the immune-stimulating molecule OX40L gene in the influenza virus nonstructural (NS1) protein gene. The oncolytic effect of IAV-OX40L was explored on hepatocellular carcinoma (HCC)HCC cells in vitro and in vivo. Results: Hemagglutination titers of the IAV-OX40L virus were stably 2 7 – 2 8 in specific-pathogen-free chicken embryos. The morphology and size distribution of IAV-OX40L are similar to those of the wild-type influenza. Expression of OX40L protein was confirmed by Western blot and immunofluorescence. MTS assays showed that the cytotoxicity of IAV-OX40L was higher in HCC cells (HepG2 and Huh7) than in normal liver cells (MIHA) in a time- and dose-dependent manner in vitro. We found that intratumoral injection of IAV-OX40L reduced tumor growth and increased the survival rate of mice compared with PR8-treated controls in vivo. In addition, the pathological results showed that IAV-OX40L selectively destroyed tumor tissues without harming liver and lung tissues. CD4 + and CD8 + T cells of the IAV-OX40L group were significantly increased in the splenic lymphocytes of mice. Further validation confirmed that IAV-OX40L enhanced the immune response mainly by activating Th1-dominant immune cells, releasing interferon-γ and interleukin-2. Conclusion: Taken together, our findings demonstrate the novel chimeric influenza OV could provide a potential therapeutic strategy for combating HCC and improve the effectiveness of virotherapy for cancer therapy. Keywords: OVs, OX40L, IAV, HCC Hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors worldwide, accounting for a large proportion of cancer mortality. 1 Considerable progress has been made in the treatment of HCC, but the therapeutic efficacy is still not ideal. 2,3 Previous studies have shown that HCC is mainly caused by immune escape and proliferation of tumor cells. 4,5 Simultaneously, tumor cells create an immune microenvironment with the participation of various cell types, allowing the tumor cells to escape from immune supervision, survival, and proliferation. 6 Cancer immunotherapy relies on the recognition of tumor-associated antigens, which can restore the patient's immune response against tumor cells. 7 In recent years, many researchers have been interested in methods of improve the effectiveness of immunotherapy for HCC. 8,9 Oncolytic virus (OV) therapy is a revolutionary tool for cancer immunotherapy. Tumor cells have defective damage- or pathogen-recognition responses, which make them more susceptible to viral infection. OVs can replicate and destroy tumor cells without affecting normal cells. 10,11 The mechanisms underlying the antitumor effects of OVs include targeted oncolytic effects and activation of the host's innate and adaptive immune responses. 12,13 OVs kill tumor cells directly and alter the tumor microenvironment to result in tumor cell destruction. 14,15 With the development of genetic engineering techniques, a variety of viral vectors can be engineered to express immunoregulatory genes for cancer treatment, these viral vectors include influenza virus, herpes virus, adenovirus, and so on. Such methods can be u -Abstract Truncated-
oncology